Equities

Intellego Technologies AB

Intellego Technologies AB

Actions
  • Price (SEK)29.55
  • Today's Change-0.45 / -1.50%
  • Shares traded61.10k
  • 1 Year change+111.37%
  • Beta--
Data delayed at least 15 minutes, as of May 03 2024 11:22 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Intellego Technologies AB is a Sweden-based company engaged in photochromatic indicator technology. The Company is a manufacturer of colorimetric ultraviolet indicators. UVC Dosimeters are used in Healthcare, Hospitality, Retail, Transportation and Commercial Applications around the world. With its patented photochromic ink that changes color based on exposure to ultraviolet irradiation or specific substances, Intellego produces dosimeters in a variety of formats and custom options to meet the constantly evolving needs of Ultraviolet Device Manufacturers (OEMs) and end-users. Intellego Technologies is headquartered in Stockholm, with product development and manufacturing based in the southwest region of Sweden.

  • Revenue in SEK (TTM)186.49m
  • Net income in SEK59.61m
  • Incorporated2011
  • Employees68.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Enzymatica AB (publ)47.29m-53.67m508.01m18.00--6.05--10.74-0.3247-0.32470.28660.48410.32691.386.48---37.11-27.36-39.16-33.9864.2565.08-113.50-66.12---23.260.2502--4.00-0.638227.57--7.02--
Promimic AB37.07m-9.22m529.87m17.00--6.91--14.29-0.5295-0.52952.084.110.3994-5.633.002,180,588.00-9.93-24.88-11.67-29.25103.90101.23-24.87-89.463.98------128.63--41.95------
Bergenbio ASA350.11k-188.31m559.76m18.00--3.05--1,598.82-0.2647-0.26470.00020.04740.0021-------111.66-66.15-176.09-78.74-----53,785.59-11,419.44----0.00---9.00-31.4336.98------
IRLAB Therapeutics AB5.68m-177.84m577.44m37.00--5.00--101.70-3.43-3.430.10952.230.0227--0.5137---71.04-27.12-82.41-30.42-2,161.57-72.18-3,132.07-155.57----0.1923---90.71216.07-56.82---22.56--
Gentian Diagnostics ASA133.67m-10.53m588.76m58.00--4.06--4.40-0.6905-0.69058.769.510.73291.767.472,330,224.00-5.77-10.76-6.62-11.8650.6141.46-7.88-26.994.13--0.0817--32.9827.6354.92---4.92--
Cantargia AB0.00-280.03m595.51m22.00--3.53-----1.65-1.650.000.91860.00----0.00-80.18-55.08-100.27-61.35------------0.00------24.69------
Orexo AB638.60m-128.40m597.02m116.00--10.06--0.9349-3.73-3.7318.551.710.67381.522.885,505,173.00-13.55-6.41-20.60-9.9986.0986.76-20.11-11.831.580.36040.8894--2.32-3.9927.76--25.77--
Oncopeptides AB35.22m-249.11m615.14m57.00--6.52--17.47-1.96-1.960.27760.44740.1129--1.44617,894.80-79.88-141.28-101.04-200.49103.06---707.30-2,689.06----0.7065--321.54--26.29------
Alligator Bioscience AB58.11m-248.59m689.82m58.00--50.58--11.87-0.5613-0.56130.12050.0180.4035--8.341,001,845.00-172.61-73.26-399.57-91.33-----427.81-811.68----0.5759--62.7816.60-28.53---20.34--
BioPorto A/S48.41m-88.08m769.41m31.00--8.18--15.89-0.1605-0.16050.08830.15850.3123.4011.96998,645.20-56.77-71.10-79.27-96.5565.1963.38-181.95-239.223.09-1,718.970.1076--6.873.5425.81---51.56--
Nightingale Health Oyj42.61m-210.60m784.68m81.00--1.15--18.41-0.2979-0.29790.06031.500.03441.603.8744,560.98-17.02-14.20-18.12-15.6975.8183.57-494.25-408.5014.15--0.0378--80.8019.05-12.38------
Intellego Technologies AB186.49m59.61m790.58m68.0012.695.2312.524.242.362.367.435.740.88413.263.692,742,544.0028.26--44.00--68.73--31.96--1.975.820.1684--222.74--493.56------
XSpray Pharma AB (publ)0.00-179.67m1.02bn26.00--1.85-----7.02-7.020.0022.190.00----0.00-26.60-18.38-28.03-19.26--------4.36--0.0504-------36.45--2.87--
Vistin Pharma ASA433.51m55.61m1.03bn77.0018.453.4914.012.371.271.279.886.701.112.317.445,692,663.0014.281.7318.932.1159.9358.9212.832.360.853632.960.0934--51.3516.951,066.84---0.1922--
Moberg Pharma AB (publ)0.00-21.09m1.05bn----1.69-----1.20-1.200.0021.840.00-------3.52---3.66----------3.04--0.0077---100.00---34.26------
Data as of May 03 2024. Currency figures normalised to Intellego Technologies AB's reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.